| 引用本文:魏恩垚，张文斌，李世川，陈果.利肺片治疗稳定期支气管哮喘的临床疗效及对血清基质金属蛋白酶-9表达的影响[J].世界中医药,2018,(05):. |
|
| 利肺片治疗稳定期支气管哮喘的临床疗效及对血清基质金属蛋白酶-9表达的影响 |
| Clinical Curative Effects of Lifei Tablets on the Stabilization of Bronchial Asthma and the Changes of Serum Level of MMP-9 |
| 投稿时间：2017-09-23 |
| DOI：10.3969/j.issn.1673-7202.2018.05.030 |
| 中文关键词: 呼吸道疾病 支气管哮喘 稳定期 利肺片 中医证候积分 肺功能 基质金属蛋白酶-9 气道重塑 |
| English Keywords:Respiratory disease Bronchial asthma Stable phase Lifei tablets TCM syndrome integral Lung function MMP-9 Airway remodeling |
| 基金项目:重庆市卫生局2011年科研计划项目（2011-1-138） |
|
| 摘要点击次数: 936 |
| 全文下载次数: 812 |
| 中文摘要: |
| 目的：观察利肺片治疗稳定期支气管哮喘的效果，并研究其对基质金属蛋白酶-9(Matrix Metalloprotein-9,MMP-9）的干预效应。方法：选取2015年1月至2016年12月支气管稳定期患者60例，随机分为对照组和观察组，每组30例。2组患者均接受口服氨茶碱片，0.1 g/次，3次/d。观察组在此治疗基础上加用利肺片，2片/次，3次/d,2组均以20 d为1个疗程，疗程结束后比较2组患者中医证候积分、肺功能、哮喘指标复常时间以及血清MMP-9。结果:2组单项及总的中医证候积分均较治疗前下降（P<0.05），观察组改善更明显（P<0.05）；观察组临床总有效率90.00%，对照组临床总有效率76.66%，差异有统计学意义（P<0.05）；3观察组患者哮喘指标的复常时间较对照组缩短，差异有统计学意义（P<0.05）；2组治疗后第1秒用力呼气肺容积(FEV1)、呼气峰流量(PEF)及第1秒用力呼气容积/用力肺活量(FEV1/FVC)均较治疗前改善（P<0.05），其中观察组改善得趋势更明显，与对照组比较，差异有统计学意义（P<0.05）；2组治疗后MMP-9水平有所下降，与对照组比较，观察组治疗后MMP-9水平更低（P<0.05）。结论：常规治疗基础上，利肺片可进一步缓解支气管哮喘病情，安全性高。 |
| English Summary: |
| To observe the effects of Lifei tabled on the stable phase of bronchial asthma, and to study the intervention effects on matrix metalloproteinases 9 (matrix metalloprotein-MMP of 9) concentration.Methods:A total of 60 patients with bronchial in the stable phase who treated in our hospital included into the study, were randomly divided into the control group and the observation group, with 30 cases in each group.Two groups of patients both received aminophylline tablets, 0.1 g/time, 3 times/day.The observation group had Lifei tables based on the treatment on the basic treatment, 2 tablets/times, 3 times/day.Both groups had 20 days for a course of treatment.After treatment, TCM syndrome integrals, pulmonary function, asthma indexes and the changes of serum concentration of MMP – 9 of two groups were compared.Results:1) The single and general TCM syndrome integrals decreased in the two groups of patients than before treatment (P<0.05), and the improvement of the observation group was more significantly (P<0.05); 2) The clinical total effective rate of the observation group was 90%, and 76.66% in the control group.The differences were with statistically significant (P<0.05); 3) The recovery time of patients with asthma in the observation group was shortened than the control group, with statistically significant differences (P<0.05); 4) forced expiratory volume (FEVl), peak expiratory flow (PEF) and 1st second forced expiratory lung forced vital capacity (FEVl/FVC) improved in the two groups after treatment (P<0.05), and the improved trend of the observation group was more obvious.The control group were with statistically significant differences (P<0.05); 5) Detected by ELISA test, MMP-9 levels decreased after treatment in the two groups of children, and the observation group had lower levels of MMP-9 after treatment compared with the control group (P<0.05).Conclusion:Based on conventional treatment, the Lifei tablets can further relieve state of bronchial asthma, with high safety, which is recommended in the clinical application. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
